GAL4-DBD-PPARγ-LBD-BSD

The GAL4-DBD-PPARγ-LBD-BSD fusion construct provides a robust system to investigate ligand interactions with PPARγ, using the GAL4-UAS reporter system. This tool facilitates the study of agonists (e.g., rosiglitazone) that activate PPARγ, and antagonists that modulate its activity, supporting drug discovery efforts focused on PPARγ-activating therapies. With high titer lentiviral particles and flexible readout options (GFP, RFP, or Firefly Luciferase), researchers can establish their own cell lines, eliminating the need for transient transfections—resulting in significant cost savings over time, while ensuring reliable, reproducible results.

The Peroxisome Proliferator-Activated Receptor (PPAR) family—including PPARα, PPARγ, and PPARβ/δ—plays a central role in metabolic regulation, covering pathways involved in lipid metabolism, glucose homeostasis, and inflammation. PPARγ (gamma), also known as NR1C3 and encoded by the PPARG gene, is especially significant in adipocyte differentiation and insulin sensitivity, making it a prime target in drug discovery for metabolic disorders, diabetes, and obesity. For custom nuclear receptor solutions, LipExoGen offers tailored constructs for any PPAR family member or other nuclear receptors. For custom solutions featuring alternative nuclear receptor family members, we offer similar pricing and a streamlined production timeline.

Contact us today to see how this tool can accelerate your drug discovery pipeline and therapeutic research.